ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

The In Vivo team recently put a spotlight on innovation that might disrupt the pharma and medtech markets. Thinking about novel developments today that will impact the life sciences sector in the near future, we explored interesting new science, the convergence of R&D and technology, as well as what the future of surgery might look like.